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Novelty and impact statement: This large investigation with 865 incident pancreatic cancer 
cases from the EPIC study showed no significant association between dietary folate intake 
and pancreatic cancer risk. Dietary folate intake was ascertained using the standardised folate 
dataset compiled for EPIC which provided comparable folate data across the participating 
countries with minimum influence of folic acid fortification or supplementation.A
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Abstract  1 
Pancreatic cancer (PC) has an exceptionally low survival rate and primary prevention 2 
strategies are limited. Folate plays an important role in one-carbon metabolism and has been 3 
associated with the risk of several cancers, but not consistently with PC risk. We aimed to 4 
investigate the association between dietary folate intake and PC risk, using the standardised 5 
folate database across 10 European countries. A total of 477,206 participants were followed 6 
up for 11 years, during which 865 incident primary PC cases were recorded. Folate intake 7 
was energy-adjusted using the residual method. Hazard ratios (HRs) and 95% confidence 8 
intervals (CIs) were estimated using Cox proportional hazards models. In multivariable 9 
analyses stratified by age, sex, study centre and adjusted for energy intake, smoking status, 10 
BMI, educational level, diabetes status, supplement use and dietary fibre intake, we found no 11 
significant association between folate intake and PC risk: the HR of PC risk for those in the 12 
highest quartile of folate intake (≥353 μg/d) compared with the lowest (<241 μg/d) was 0.81 13 
(95% CI: 0.51, 1.31; Ptrend = 0.38). In current smokers, a positive trend was observed in PC 14 
risk across folate quartiles (HR=4.42 (95% CI: 1.05, 18.62) for ≥353 μg/d vs. <241 μg/d, 15 
Ptrend = 0.01). Nonetheless, there was no significant interaction between smoking and dietary 16 
folate intake (Pinteraction= 0.99). We found no association between dietary folate intake and PC 17 
risk in this large European study. 18 
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Introduction 19 
The diagnosis of pancreatic cancer (PC) is rarely made at an early stage and it has an 20 
exceptionally low survival rate due to a late diagnosis and limited treatment options, making 21 
it the seventh leading cause of cancer death worldwide with an almost equal number of new 22 
cases diagnosed each year1. The burden of this cancer is increasing with an aging population, 23 
and is particularly high in more developed countries. The incidence of pancreatic cancer 24 
varies greatly across regions, which suggests a role of environmental, dietary or lifestyle 25 
factors 2, 3. Consistently identified risk factors for pancreatic cancer include tobacco smoking, 26 
body fatness, conditions characterized by high insulin secretion, chronic pancreatitis, heavy 27 
alcohol intake and family history of the disease4-6. Nonetheless, the aetiology of the cancer is 28 
largely unknown and prevention strategies are limited. 29 
Folate, naturally available in a wide variety of foods including fruits and vegetables, is a 30 
water-soluble vitamin B that plays an important role in the synthesis and methylation of DNA 31 
as a crucial cofactor in one-carbon metabolism together with other B vitamins such as 32 
vitamin B2, vitamin B6 and vitamin B127. Inadequate folate status may contribute to 33 
carcinogenesis through aberrations in DNA methylation and uracil misincorporation, leading 34 
to DNA instability 7-9.  35 
Previous epidemiological studies have shown inconsistent results for associations 36 
between folate status and pancreatic cancer risk suggesting a weak inverse association with 37 
dietary folate intake from natural sources, but not from supplements 10-14. A recent meta-38 
analysis supported this observation15 whereas a large pooled analysis of 14 prospective cohort 39 
studies found no association 16. In the former meta-analysis, the overall estimates were from 40 
both case-control and prospective cohort studies, and a significant heterogeneity was found 41 
across those studies. In the latter pooled analyses, folate data might not be comparable across 42 
studies and countries due to the use of various databases and analytical methods, thus 43 
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attenuating potential relationships with pancreatic cancer. A recent meta-analysis of 44 
randomised trials of folic acid supplementation with an average duration of 5 years of 45 
treatment found no significant effect on overall or site-specific cancer incidence including 46 
pancreatic cancer 17. The results from plasma measurements of folate intake in association 47 
with pancreatic cancer were also inconclusive 18-20. In a more recent nested case-control study 48 
in the EPIC cohort, including 463 incident pancreatic cancer case, a weak U-shaped 49 
association was observed between plasma folate and pancreatic cancer risk18.  50 
The aim of this study was to investigate the association between dietary folate intake and 51 
pancreatic cancer risk within the European Prospective Investigation into Cancer and 52 
Nutrition (EPIC) study, benefitting from a large number of cases with an extended follow-up 53 
time and standardised dietary folate intake data from a comprehensive EPIC Nutrient 54 
DataBase (ENDB) where folate information was harmonized using common procedures and 55 
guidelines, with support from the local national compilers in 10 countries participating in 56 
EPIC21.  57 
 58 
Subjects and Methods     59 
Study population 60 
The EPIC study is a multicentre prospective cohort study designed to investigate the 61 
associations between diet and various lifestyle, environmental risk factors and the incidence 62 
of different cancers and other chronic diseases. The full rationale and methods of the study 63 
were reported elsewhere 22, 23. Briefly, the EPIC cohort consists of 23 study centres in 10 64 
European countries (Denmark, France, Greece, Germany, Italy, Netherlands, Norway, Spain, 65 
Sweden, and the UK), with over 521,330 participants. EPIC participants were mostly 66 
recruited from the general population residing within defined geographical areas between 67 
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1992 and 2000, with some exceptions: women members of a health insurance for school 68 
employees (France); women attending breast cancer screening (Utrecht, the Netherlands, 69 
Florence, and Italy); blood donors (centres in Italy and Spain) and a cohort with a large 70 
proportion (approximately 50%) of vegetarians (‘health conscious’ cohort in Oxford, UK). 71 
The participants completed dietary and lifestyle questionnaires and had their anthropometric 72 
measurements recorded by trained health professionals (self-reported in France, Norway and 73 
Oxford). All participants gave their written informed consent, and the study was approved by 74 
the local ethics committee in the participating countries and the Ethics Committee of the 75 
Internal Agency for Research on Cancer, Lyon, France. 76 
  Our study is based on data from 477,206 participants (142,228 men and 334,978 77 
women) after a priori exclusion of individuals with prevalent cancer at recruitment, missing 78 
diagnosis or censoring date, missing dietary or lifestyle information, and implausible extreme 79 
values in the top and bottom one percent of the distribution of the ratio of reported total 80 
energy intake to estimated energy requirement (estimated from age, sex, and body weight and 81 
height).  82 
 83 
Diet and lifestyle data 84 
Diet including folate and other B vitamins over the previous 12 months was measured by 85 
country/centre-specific validated dietary assessment methods, mostly food frequency 86 
questionnaire designed to capture local dietary habits and to allow high compliance. The 87 
relative validity and reproducibility of the questionnaires has previously been published 24. 88 
The questionnaire, validated within each count ry, was self-administered in all centres, except 89 
in Greece, two Italian centres, and Spain, where it was administered by interviewers.  90 
Dietary folate intake was estimated using the updated EPIC Nutrient DataBase (ENDB)21. 91 
The ENDB project was initiated and nutrient databases were harmonized using common 92 
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procedures and guidelines, with support from the local national compilers in 10 countries in 93 
EPIC 25. The ENDB was first completed for 26 priority components to provide a standardised 94 
reference instrument for calibrating the EPIC dietary measurements at the nutrient level 26. 95 
This work has been extended to cover other nutrients including folate and other B vitamins21 96 
Although the ENDB values were obtained from country-specific food composition tables, 97 
they were standardized as much as possible across the EPIC countries by matching of EPIC 98 
foods to the national databases according to the recommendation given in a recent review21. 99 
In particular, a microbiological assay was chosen as the reference analytical method for folate 100 
values in the ENDB. Folate values of unavailable foods were derived by recipe calculation or 101 
borrowed from similar foods21. During the ENDB compilation for folate, to address the issue 102 
of voluntary fortification of breakfast cereals particularly in the UK and France where cereal 103 
consumption was substantially higher, aggregation was re-done taking into account the brand 104 
names and folic acid fortification levels of cereals21. 105 
In the Scandinavian countries and in the Netherlands, folate fortification was not allowed 106 
at the time of data collection. In other EPIC countries, breakfast cereal consumption was very 107 
low and the information on folic acid-fortified foods was not always available21. It was 108 
therefore, decided not to adopt the dietary folate equivalent (DFE) conversion which 109 
considers lower bioavailability of naturally occurring folate compared to synthetic folic acid. 110 
Information on dietary intakes of other nutrients including other B vitamins was also 111 
estimated using the ENDB. 112 
Self-reported data on lifestyle factors, including total physical activity, educational level, 113 
smoking history, diabetes status and ever use of vitamin or mineral supplements considered 114 
in the analysis were collected at baseline through standardised questionnaires and clinical 115 
examinations, and have been described elsewhere 23, 27-30.  116 
 117 
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Endpoints 118 
Incident pancreatic cancer cases were identified through population cancer registries 119 
(Denmark, Italy, Netherlands, Norway, Spain, Sweden, and the UK) or by active follow-up 120 
(France, Germany, Naples, and Greece). The active follow-up procedure used a combination 121 
of different strategies, including health insurance records, cancer and pathology registries, 122 
and contacts with participants and their next of kin 23. Participants were followed up from 123 
study entry until cancer diagnosis (except non-melanoma skin cancer), death, emigration or 124 
until the end of the follow-up period, whichever occurred first. Forty-five cases were 125 
censored because the tumours were neuroendocrine (n = 42), benign (n = 1), carcinoma in 126 
situ (n = 1), or with uncertain primary origin (n = 1). After a mean follow-up of 127 
approximately 11 years, 865 first incident pancreatic cancers were available for analysis and 128 
were classified corresponding to the International Classification of Diseases 10th revision as 129 
C25 (C25.0–C25.3 and C25.7–C25.9). 130 
 131 
Statistical analysis 132 
Multivariable Cox proportional hazard models were fitted to estimate the hazard ratios (HRs) 133 
and 95% confidence intervals (CIs). Disease models were fitted with intake of folate and 134 
other B vitamins as continuous variables and categorisation of the variables in quartiles based 135 
on the distribution of the whole study population. Dietary folate intake and other nutrients 136 
were energy adjusted using the residual method 31. To preserve the geographical specificity in 137 
the dietary assessment in EPIC, centre-specific residuals for total dietary folate were 138 
computed. Centre-specific mean values were then added to residuals to recuperate the 139 
original scale and ease interpretability.  140 
The following potential confounders were considered based on the literature review: total 141 
energy intake (kcal/d), BMI (kg/m2), physical activity (<moderately inactive/≥moderately 142 
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active), smoking status (never/former/current), education (<secondary school/ ≥secondary 143 
school), ever use of vitamin or mineral supplements (no/yes), history of diabetes (no/yes) and 144 
intake of other dietary factors (g/day) including dietary fibre, carbohydrate, and alcohol. In 145 
the multivariable models, the variables that changed the unadjusted risk estimate by at least 146 
~10% were considered as confounders and adjusted for. These include smoking status, BMI, 147 
educational level, history of diabetes, supplement use and dietary fibre intake. Energy intake 148 
was further included in the model for complete energy adjustment 31 even though it did not 149 
alter the unadjusted risk substantially. 150 
Quartiles of dietary folate intake were determined on the basis of the whole cohort, with 151 
the lowest quartile as the reference. Disease models were stratified by age at recruitment, sex, 152 
and study centre (Model 1) and adjusted for smoking status, total energy intake and BMI, 153 
education, diabetes status, supplement use and dietary fibre intake (Model 2). A test for trend 154 
was made by modelling a score variable using quartile-specific medians as a continuous 155 
variable. In addition, the association between dietary folate and the risk of pancreatic cancer 156 
was examined using four-knot restricted cubic splines32 with the median of the fifth decile of 157 
folate intake as the reference category. 158 
Alcohol intake was not considered as a covariate in the models as it did not change the 159 
unadjusted risk estimates. However, alcohol has a role as a folate antagonist and has been 160 
shown to have suppressive effects on methyl group metabolism 33, and we investigated the 161 
association according to tertiles of alcohol consumption. Likewise, we further explored the 162 
association between dietary folate intake and pancreatic cancer risk stratified by smoking 163 
status as smoking has been the most consistently known risk factor for pancreatic cancer and 164 
current smoking status was related to lower dietary folate intake 34. Models with main effects 165 
and cross-product terms were fitted to test for interactions. 166 
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The effect of very high (≥500 µg/d) or very low folate intake ( <150 µg/d) in relation to 167 
pancreatic cancer risk was additionally explored, with the reference category set at 200-300 168 
µg/d, which was observed to be the average intake range in a previous EPIC study comparing 169 
standardised dietary folate intake across ten participating countries34.  170 
A model including the combined effects of folate tertiles and three smoking categories in 171 
relation to overall pancreatic cancer risk was developed and the joint effects was presented in 172 
comparison with never smokers in the highest folate tertile as a reference. 173 
Sensitivity analyses were performed 1) excluding any dietary supplement users to examine 174 
a possible impact of supplement use on the association between dietary folate and pancreatic 175 
cancer risk 2) excluding the cases diagnosed within the first 2 years of follow-up to assess 176 
possible influence of preclinical factors that might cause a change in diet among participants 177 
and 3) excluding the microscopically non‐confirmed cases (n = 257) to minimize possible 178 
misclassification of tumours.  179 
All statistical tests were two-sided and analyses were performed using STATA (version 180 
13, Stata Corporation, College Station, Texas).  181 
 182 
Results 183 
A total of 477,206 participants without any history of cancer and with complete dietary folate 184 
information were included in the analysis among which 397 men and 468 women developed 185 
a first primary pancreatic cancer during an average of 11 years of follow-up. Table 1 shows 186 
baseline characteristics of the participants according to quartiles of energy-adjusted dietary 187 
folate intake. Participants in the highest category of folate intake tended to be more educated, 188 
were less likely to report being a current smoker and more likely to be physically active or 189 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved.
12 
dietary supplement users; and consumed more dietary fibre, fruit and vegetables compared 190 
with those with lower dietary folate intake.  191 
When we investigated energy-adjusted folate intake as a continuous variable in 192 
association with pancreatic cancer in the fully adjusted model, we found an HR of 1.03 (95% 193 
CI: 0.83, 1.28; P=0.78) for an increment of 100 μg/day of dietary folate intake 194 
(approximately 1 SD). When folate intake was categorised into quartiles, higher dietary folate 195 
intake showed a borderline statistically significant association with lower risk of pancreatic 196 
cancer (Model 1, Table 2). The trend became attenuated and did not reach statistical 197 
significance in Model 2 after multivariable adjustment (Table 2): the multivariable HR of 198 
pancreatic cancer for those in the highest category of folate intake (≥353 μg/day) compared 199 
with the lowest category of intake (<241 μg/day) was 0.81 (95% CI: 0.51, 1.31; Ptrend = 0.38). 200 
Among the variables included in the Model 2, smoking and dietary fibre intake changed the 201 
unadjusted risk estimate most. Our non-linear multivariable modelling of the association 202 
using cubic spline confirmed no significant trend (Figure 1). Further analysis using 203 
continuous folate intake with a quadratic term provided no evidence of a non-linear 204 
association between folate intake and pancreatic cancer risk (Pquadratic term=0.56). 205 
When we investigated the association according to alcohol consumption, there was no 206 
evidence of a differential relationship according to levels of alcohol intake (Pinteraction= 0.82, 207 
Table 2). In a subgroup analysis by smoking status we observed an increased risk of 208 
pancreatic cancer with increasing folate intake in current smokers while no significant 209 
associations were observed in never and former smokers: the multivariable HR of pancreatic 210 
cancer among current smokers and those who had folate intake between 292 and 352 μg/day 211 
and those who consumed more than 353 μg/day compared with the lowest category were 4.52 212 
(95% CI: 1.59, 12.88) and 4.42 (95% CI: 1.05, 18.62), respectively (Ptrend = 0.01, Table 2). 213 
The results did not differ when alcohol was additionally adjusted for. Nonetheless, an 214 
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interaction test with smoking and folate intake for the risk of pancreatic cancer was not 215 
statistically significant (Pinteraction= 0.99). 216 
The characteristics of the participants in this study varied according to their smoking 217 
status. Current smokers were younger, more likely to be men, to have a lower educational 218 
level, and less likely to be diabetic at baseline, tended to have lower folate, fibre, fruit and 219 
vegetable intakes and consumed more alcohol compared to never smokers (data not shown). 220 
Further alcohol adjustment in the main models did not change the risk estimates stratified by 221 
smoking status. When we considered smoking intensity in current smokers by adjusting for 222 
number of cigarettes smoked per day, the results showed a greater than five-fold increased 223 
risk in those who had a folate intake of more than 292 μg/d (data not shown). 224 
 The observed increased risk of pancreatic cancer with higher folate intake in current 225 
smokers was further explored by choosing one single reference category (≥330 μg/day of 226 
dietary folate intake and never smoker) and combined effects were determined for tertiles of 227 
folate intakes in combination with categories of smoking status in relation to pancreatic 228 
cancer risk (Figure 2). A more than 50% increase in pancreatic cancer risk was observed in 229 
current smokers regardless of the levels of folate intake, although a significantly higher risk 230 
was observed among those who consumed more than 258 μg/day of folate.  231 
We also explored the effect of very high (≥500 µg/d) or very low folate intake (<150 232 
µg/d) in relation to pancreatic cancer risk, and we did not observe any significant associations 233 
in the multivariable adjusted model, possibly due to limited statistical power (Table 3).  234 
When we conducted a sensitivity analysis among those who reported not to take any 235 
dietary supplements (n=237,113), the results did not change substantially (HR of 0.90, 95% 236 
CI: 0.60, 1.35; P=0.61 for an increment of 100 μg/day folate, HR for the highest quartile vs. 237 
lowest: 0.61, 95% CI: 0.26, 1.44; Ptrend = 0.28). Similarly, the results hardly changed when 238 
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we excluded the pancreatic cancer cases incident within the first 2 years of follow-up (n=90 239 
cases) and repeated the analyses (HR of 1.03, 95% CI: 0.82, 1.29; P=0.79 for an increment of 240 
100 μg/day, HR for the highest quartile vs. lowest: 0.79, 95% CI: 0.48, 1.30; Ptrend = 0.32). A 241 
sensitivity analysis restricting the analyses to the microscopically confirmed cases did not 242 
alter the results. 243 
 244 
Discussion 245 
To our knowledge, this study that analysed 865 incident pancreatic cancer cases, is the 246 
largest single study so far that investigated the association between dietary folate intake and 247 
pancreatic cancer risk. Within a unique international setting of European populations with 248 
diverse dietary habits and lifestyle characteristics, we found no overall association between 249 
dietary folate intake and pancreatic cancer risk.  250 
There have been relatively few published single prospective studies that examined the 251 
association between dietary folate intake and pancreatic cancer risk (summarised in Table 4). 252 
Previous studies showed inconsistent results: they were heterogeneous by sex, ranges of 253 
dietary folate intake, supplement use, and confounding factors that were adjusted for in the 254 
analyses (Table 4). Including studies conducted in the US, where dietary supplement use is 255 
widespread, there is little evidence that folic acid intake from supplements was associated 256 
with pancreatic cancer risk, while dietary folate intake was shown to be possibly related with 257 
lower risks in some, but not in all studies (Table 4). Only one study from the US was able to 258 
distinguish the difference in dietary folate intake from natural sources and from folic acid 259 
fortification 12. In this study, no association was found in men, while women in the highest 260 
quartile of food folate intake showed a significant 53% reduction in pancreatic cancer risk 261 
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compared with those in the lowest quartile. No significant association was found between 262 
supplemental folic acid use and pancreatic cancer risk 12.  263 
Three meta-analyses15, 35, 36 have reported a generally decreased risk of pancreatic cancer 264 
with increasing dietary folate intake based on the above mentioned cohort studies together 265 
with case-control studies, with significant heterogeneity reported in the two15, 36. The 2012 266 
Continuous Update Project (CUP) Report of the WCRF/AICR Export Report weakened the 267 
conclusions from the 2007 Expert Report, after reviewing evidence from five prospective 268 
cohort studies, concluding the evidence is too inconsistent to allow a firm conclusion to be 269 
drawn4.   270 
A large pooled analysis of 14 prospective cohort studies showed that dietary folate intake 271 
was not associated with overall risk of pancreatic cancer 16. The summary relative risk for the 272 
highest vs. the lowest quintile of folate intake was 1.06 (95% CI: 0.90-1.25, Pheterogeneity=0.15) 273 
16
. In the pooled analysis, folate data may be heterogeneous across studies and countries as 274 
studies rely on each country’s own food-composition data which tend to vary in terms of 275 
availability and quality of folate values 37, 38. This may have an influence in a potential 276 
relationship. It has been pointed out that there is a lack of clarity and consistency in the 277 
terminology and definitions used for folate information in the food composition tables 278 
available in Europe due to the specific complexity of folate 39. A recent critical evaluation of 279 
folate data in 18 European and international databases concluded that a lack of comparability 280 
still exists between countries 40. To overcome this, our study results came from the 281 
standardised food and nutrient data linked to the ENDB with recently updated folate 282 
information.  283 
Despite the recent increasing use of dietary supplements in many European countries, the 284 
use of folic acid supplement was not a common practice when our baseline data were 285 
collected 10, 41. Indeed, folic acid-containing supplements were not among the most frequently 286 
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consumed types of supplements in the EPIC study according to the 24 hour-recall data that 287 
were collected in a sub group of participants with more detailed information on supplement 288 
use at the baseline 41. In addition, folic acid fortification was not widespread at the time of the 289 
baseline information collection in Europe21. Thus, we had the unique opportunity to assess 290 
the association between baseline dietary folate intake and pancreatic cancer risk, with 291 
minimum influence of folic acid fortification or supplementation in the EPIC study. This was 292 
confirmed when we conducted a sensitivity analysis excluding ever users of vitamin and 293 
mineral supplements and the results did not materially change.  294 
In our study, we observed a greater than four-fold elevated risk in current smokers with 295 
higher dietary folate intake while in never or former smokers the risks were lower and non-296 
significant. Current smokers have a higher chance to harbour precursor lesions in the 297 
pancreas, and increased availability of folate may promote proliferation of already existing 298 
neoplastic cells 42, 43. We investigated this further by excluding cases diagnosed within the 299 
first two or three years of follow-up which did not alter the results. Previous studies have 300 
shown inconsistent results with regards to smoking status. While a previous EPIC nested 301 
case-control study that investigated plasma folate levels in relation to pancreatic cancer risk 302 
did not show any heterogeneity across smoking status18, an inverse association with 303 
pancreatic cancer risk was reported with both dietary folate intake14 and serum folate levels19 304 
in a cohort of Finnish male smokers. In the large pooled analysis of cohort studies, there was 305 
no effect modification by smoking status with dietary folate intake16. Although increased 306 
pancreatic cancer risk observed in current smokers in our study, especially in participants 307 
with dietary folate intake higher than 292 μg/day may be worth exploring further in future 308 
studies, few cases included, no statistically significant interaction found, potential role of 309 
residual confounding or chance require cautious interpretation of the results. 310 
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17 
The current study has limitations. We did not have information on occurrence of 311 
pancreatitis in the study population which might have affected pancreatic cancer risk. Neither 312 
did we have repeated information during the follow-up period to assess any potential changes 313 
in dietary intakes over time. In addition, we relied on self-reported dietary folate intake. 314 
However, the overall results did not substantially differ from the previous EPIC study that 315 
investigated plasma folate level in association with pancreatic cancer risk18.  In our study, the 316 
range of dietary folate intake was quite narrow, as shown previously in the results using the 317 
24-hour dietary recall methods 34, with too few participants with either very low or very high 318 
intakes. It was therefore not possible to explore the effect of extreme folate intake on 319 
pancreatic cancer risk with sufficient statistical power. We used self-reported smoking status 320 
which might be inaccurate. However, a recent EPIC study of plasma cotinine level and 321 
pancreatic cancer risk compared the cotinine level against self-reported smoking status and 322 
concluded that self-reported smoking status was sufficient to establish a causal relationship 323 
and did not underestimate its relationship with pancreatic cancer risk 44. 324 
In conclusion, using standardised data from this large, multi-centre prospective study, we 325 
found no association between dietary folate intake and pancreatic cancer risk. 326 
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Data sharing statement: For information on how to submit an application for gaining access 
to EPIC data and/or biospecimens, please follow the instructions at 
http://epic.iarc.fr/access/index.php. 
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Range
Cases/all participants
Men
Women
Personyears
Sex
Men
Women
Age (years) 50.2 ( 9.0 ) 51.5 ( 9.3 ) 52.3 ( 9.9 ) 50.9 ( 11.3 )
BMI (kg/m2) 25.4 ( 4.1 ) 25.6 ( 4.3 ) 25.6 ( 4.4 ) 25.0 ( 4.4 )
Smoking status
Never (%)
Former (%)
Current (%)
Educational level
<Secondary school (%)
≥Secondary school (%)
Physical activity
< moderately inactive (%)
> moderately active (%)
Dietary supplement user
No (%)
Yes (%)
Selfreported diabetes
No (%)
Yes (%)
Energy intake (Kcal) 2,062 ( 678 ) 2,064 ( 614 ) 2,067 ( 602 ) 2,092 ( 611 )
Alcohol intake (units/week)1,2 6.20 ( 15.27 ) 8.36 ( 16.15 ) 8.13 ( 13.89 ) 6.23 ( 11.17 )
Fibre intake (g/day)2 18.39 ( 4.16 ) 21.61 ( 4.45 ) 23.59 ( 4.93 ) 27.54 ( 6.67 )
Folate intake (+g/d)1,2 211.82 ( 35.04 ) 266.36 ( 25.44 ) 319.59 ( 29.62 ) 408.31 ( 89.83 )
Vitamin B12 intake (+g)1,2 5.51 ( 2.68 ) 5.96 ( 3.19 ) 6.09 ( 3.74 ) 6.02 ( 4.55 )
Vitamin B6 intake (mg)2 1.53 ( 0.32 ) 1.76 ( 0.31 ) 1.95 ( 0.33 ) 2.25 ( 0.44 )
Riboflavin intake (mg)2 1.47 ( 0.36 ) 1.70 ( 0.42 ) 1.93 ( 0.50 ) 2.34 ( 0.72 )
Meat and meat products intake (g/day)1 93.5 ( 68.3 ) 97.7 ( 69.2 ) 94.4 ( 71.6 ) 78.7 ( 91.9 )
Vegetable intake (g/day)1 97.9 ( 69.6 ) 145.6 ( 94.8 ) 210.4 ( 134.1 ) 321.3 ( 192.7 )
Fruits, nuts and seeds intake (g/day)1 123.5 ( 137.7 ) 178.9 ( 176.1 ) 232.9 ( 204.1 ) 292.5 ( 246.9 )
231/119,302 234/119,301 228/119,302 172/119,301
133/44,758 106/38,789 95/33,284 63/25,397
Energyadjusted folate intake (+g/d)
Q1 Q2 Q3 Q4
0/241 241/292 292/353 ≥353
37.5 32.5 27.9 21.3
98/74,544 128/80,512 133/86,018 109/93,904
1,320,250 1,321,789 1,309,460 1,313,115
27.4 27.8 26.0 27.4
30.2 25.6 20.9 14.4
62.5 67.5 72.1 78.7
42.4 46.6 53.1 58.2
62.1 57.5 53.7 42.7
37.9 42.5 46.3 57.3
58.1 56.4 56.9 55.6
41.9 43.6 43.1 44.4
32.6 37.0 42.5 47.1
67.4 63.0 57.5 52.9
98.1 97.4 96.6 96.4
1.9 2.6 3.4 3.7
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Table 3 Hazard ratios of pancreatic cancer, with 95% confidence intervals (CIs), according to different categories of energy-adjusted dietary folate intake, with 200-300 µg/d of folate intake being a 
reference 
 
1
 Folate intake was adjusted for energy using the residual method. 
2
Model1 was with stratification of sex, age and centre. 
3 
Model2 was adjusted for smoking status, energy intake and BMI, 
education, diabetes status (self-reported), supplement use and fibre intake, and age, sex and centre being included as stratification variables. 
 
200 to <300 µg/d
P for      
trend
No. of all participants 216,143
Pancreatic cancer cases 420
Person-years 2,392,501
Model1
2
2.72 ( 1.16 ­ 6.39 ) 0.81 ( 0.53 ­ 1.24 ) 1.00 0.82 ( 0.64 ­ 1.05 ) 1.17 ( 0.55 ­ 2.52 ) 0.34
Model2
3
1.82 ( 0.70 ­ 4.73 ) 0.73 ( 0.47 ­ 1.14 ) 1.00 0.89 ( 0.67 ­ 1.18 ) 1.61 ( 0.67 ­ 3.86 ) 0.77
45,102 401,302 2,200,878 224,725
4,013 36,330 200,438 20,282
17 58 344 26
Energy-adjusted folate intake
1
<150 µg/d 150 to <200 µg/d 300 to <500 µg/d ≥500 µg/d
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Oaks et al, 
2010 (US)
The Prostate, 
Lung, 
Colorectal, and 
Ovarian Cancer 
Screening Trial 
cohort
51,988 men 
and 57,187 
women
55%74
Dietary food 
folate (natural 
+ fortified) 
intake (124%
item FFQ data)
6.5
266 incident 
pancreatic 
cancer cases
Cox 
proportional 
hazard models
Age, total energy intake, 
smoking, self%reported 
diabetes, BMI, and 
saturated fat intake
(95% CI, 0.23%0.94; 
 tr end=0.09) for Q4 (>253.3 
<g/d) vs. Q1 (<179.1 <g/d) 
in women and  (0.70%
2.04;  tr end=0.67) for Q4 
(>229.6 <g/d) vs. Q1 
(<158.0 <g/d) in men 
The results 
 an 
association between higher 
food (natural+fortified) and 
total folate intakes and 
decreased risk of pancreatic 
cancerbut not in 
men
The findings show no 
association between folic 
acid added to foods and 
pancreatic cancer risk (and 
also do not support the 
hypothesis that folic acid 
fortification increases the 
risk of pancreatic cancer)
Keszei et al, 
2009 (The 
Netherlands)
The Netherlands 
Cohort Study
5,000 men 
and women 
(case%cohort 
design)
55%69
Dietary folate 
intake (150%
item FFQ data)
13.3
363 incident 
pancreatic 
cancer cases
Cox 
proportional 
hazard models
Age, sex, smoking status, 
number of years smoked, 
number of cigarettes 
smoked, intake of 
vegetables and added 
sugar
 (95% CI, 0.97%1.94; 
 tr end=0.07) for Q5 (>259.1 
<g/d in men, >233.1 <g/d 
in women) vs. Q1 (<176.3 
<g/d in men, <154.1 <g/d 
in women) 
The results 
 a 
protective association of total 
dietary folate intake on the 
risk of pancreatic cancer
Folic acid in vitamin 
supplements was not 
allowed until the mid 
nineties, the effect of folic 
acid supplementation is 
therefore negligible
Larsson et al, 
2006 (Sweden)
The Swedish 
Mammography 
Cohort+the 
Cohort of 
Swedish Men
81,922 men 
and women 
45%83
Dietary folate 
intake (96%
item FFQ data)
6.8
135 incident 
pancreatic 
cancer cases
Cox 
proportional 
hazard models
Age, sex, smoking status, 
pack%years of somking, 
education, BMI, exercise, 
history of diabetes, 
intakes of total energy, 
alcohol, and carbohydrate 
and fruit and vegetable 
consumption
 (95% CI, 0.11%0.59; 
 tr end=0.002) for Q5 (>350 
<g/d) vs. Q1 (<200 <g/d)
The results support an 
association between increased 
intake of food folate 	 a 
reduced risk of pancreatic 
cancer
An inverse association was 
observed between intake of 
folate from foods 
(combining dietary and 
supplemental sources), but 
not from supplements, and 
the risk of pancreatic 
cancer
Skinner et al, 
2004 (US)
The Nurses' 
Health Study + 
the Health 
Professionals 
Follow%up Study
77,640 
women and 
47,840 men
30%75
Dietary folate 
intake (131%
item FFQ data)
14
326 incident 
pancreatic 
cancer cases
Cox 
proportional 
hazard models
Age, energy intake, 
cigarette smoking, BMI, 
diabetes and height
   (95% CI, 0.37%1.18; 
 tr end=0.17) for Q5 (>500 
<g/d) vs. Q1 (<300 <g/d)
The results from two large 
cohorts 
 a 
strong association between 
energy%adjusted folate intake 
and the risk of pancreatic 
cancer
No influence of 
supplemental folic acid, a 
nonsignificant inverse trend 
for folate from food sources
Stolzenberg%
Solomon et al, 
2001 (Finland)
The Alpha%
Tocopherol, Beta%
Carotene Cancer 
Prevention Study
27,101 male 
smokers
50%69
Dietary folate 
intake (276%
item FFQ data)
13
157 incident 
pancreatic 
cancer cases
Cox 
proportional 
hazard models
Age and intervention 
adjusted
 (95% CI, 0.31%0.87; 
 tr end=0.05) for Q5 (>373 
<g/d) vs. Q1 (<280 <g/d) 
The results 
 an 
inverse association between 
energy%adjusted dietary folate 
intake and the risk of 
pancreatic cancer in male 
smokers
No significant association 
found between folic acid 
supplement consumption 
and pancreatic cancer risk 
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Novelty & Impact Statement: IJC-18-0640.R1 
 
Inadequate folate intake is suspected of playing a role in the development of anomalies in DNA 
methylation, thereby contributing to carcinogenesis. In the case of pancreatic cancer, however, 
associations with folate status are unclear. The present investigation examined incident pancreatic 
cancer and dietary folate intake among subjects enrolled in the EPIC study, a multicentre prospective 
cohort study in Europe. Overall, no significant association was identified between dietary folate and 
pancreatic cancer risk. While a positive trend in risk association was detected among current smokers 
with high dietary folate, interactions between smoking and folate intake were not statistically 
significant. 
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